Tags : Yescarta

Clinical Trials

Kite Reports Results of Yescarta in P-II ZUMA-5 Study for

Shots: The P-II ZUMA-5 study involves assessing Yescarta (axicabtagene ciloleucel) in patients with r/r iNHL after at least 2L of systemic therapy. After a single infusion of Yescarta, 92% of patients responded, including 76% of patients achieving a CR @median follow-up of 17.5 mos., results presented at ASH The data supports the US FDA’s acceptance […]Read More


Kite and Kiniksa Collaborate to Evaluate the Combination of Yescarta

Shots: Kite and Kiniksa enter into a clinical collaboration to conduct a P-II study assessing Yescarta + mavrilimumab in patients with r/r LBCL. Kite will sponsor and conduct the study The P-II study will determine the effect of GM-CSFRα inhibition with mavrilimumab on the clinical safety of Yescarta. The collaboration supports Kiniksa’s objective to develop […]Read More


NICE, UK Rejects Gilead’s Yescarta for Being Too Expensive

Shots: NICE concludes that the ICER Yescarta vs salvage CT were above £50,000 per year making it expensive for use  NICE also added considering ultra-orphan diseases that ICER for Yescarta was over £100,000 per QALY (Quality Adjusted Life)  Consideration of making Yescarta available via Cancer Drug Funds has also been dropped by the committee. Consultation […]Read More


Kite’s Yescarta Receives EU Marketing Approval

Shots: Post FDA approval in 2017, Yescarta (axicabtagene ciloleucel) receives EU marketing approval for the treatment of Relapsed or Refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) The approval is based on ZUMA-1 trial with (N=101) results: 72%( 73/101) responded to therapy; 51%(52/101) achieved complete response; with one-year infusion- 60% […]Read More